Teva's Reslizumab Delivers Clinically and Statistically Significant Reduction …
Wall Street Journal Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma … |
View full post on asthma – Google News